Page last updated: 2024-08-23

dobutamine and malondialdehyde

dobutamine has been researched along with malondialdehyde in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andreadou, I; Androulakis, A; Avgeropoulou, C; Demopoulou, M; Kallikazaros, I; Markantonis-Kyroudis, S; Missovoulos, P	1

Trials

1 trial(s) available for dobutamine and malondialdehyde

Article	Year
The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. European journal of heart failure, 2005, Volume: 7, Issue:5 Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Malondialdehyde; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Pyridazines; Simendan; Time Factors; Tumor Necrosis Factor-alpha	2005

Article

Year

The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.

European journal of heart failure, 2005, Volume: 7, Issue:5

Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Malondialdehyde; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Pyridazines; Simendan; Time Factors; Tumor Necrosis Factor-alpha

2005